声门上型鳞状细胞癌:基于22,675例的人群研究
该研究利用监测、流行病学和最终结果(SEER)数据库分析1973至2013年声门上型鳞状细胞癌患者的流行病学特征、治疗趋势和结局。共纳入22,675例,平均诊断年龄62.3岁,男性占70.3%,44.9%初诊即为IV期。放疗是最常见治疗方式(46.6%),总体5年疾病特异性生存率为54.0%。
要点
- 最常见的治疗方式是放疗(46.6%),其次是手术联合放疗(29.2%)和单纯手术(15.0%)。
- 总体5年疾病特异性生存率为54.0%;按治疗方式分层,单纯手术组5年疾病特异性生存率最高(64.2%)。
- 在AJCC IV期患者中,手术联合放疗的生存显著更优(52.5%);接受手术者中,声门上喉切除术的5年疾病特异性生存率显著优于全喉切除术及未特指的喉切除术。
核心结论
- 总体而言,声门上型鳞状细胞癌最常采用放疗,其次是手术联合放疗;接受手术治疗的患者5年疾病特异性生存率优于其他治疗方式。
- 按分期分层后,AJCC IV期患者接受手术联合放疗的生存显著更优。
研究设计与样本
- 研究为基于SEER数据库的人群研究,查询1973年至2013年声门上型鳞状细胞癌患者。
- 共纳入22,675例原发性声门上型鳞状细胞癌病例,分析人口学、肿瘤大小、组织学分级、AJCC分期、SEER局部/区域/远处分期及治疗方式。
主要发现
- 诊断时平均年龄为62.3岁,男性占全部病例的70.3%。
- 44.9%的患者初诊时即为IV期疾病。
- 最常见的治疗方式为放疗(46.6%),其次为手术联合放疗(29.2%)和单纯手术(15.0%)。
- 全部病例的总体5年疾病特异性生存率为54.0%;按治疗方式分层,单纯手术组的5年疾病特异性生存率最高(64.2%)。
- 在AJCC IV期患者中,手术联合放疗的生存显著更优(52.5%)。
关键数值与推荐
- 全部病例的总体5年疾病特异性生存率为54.0%。
- 单纯手术组的5年疾病特异性生存率为64.2%,为各治疗方式中最高。
- AJCC IV期患者中,手术联合放疗的生存显著更优,5年疾病特异性生存率为52.5%。
- 接受手术的患者中,声门上喉切除术的5年疾病特异性生存率显著优于全喉切除术和未特指的喉切除术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: The authors used the Surveillance, Epidemiology, and End Results (SEER) database to analyze epidemiological features of patients presenting with supraglottic squamous cell carcinoma (SCCa) and to evaluate treatment trends and outcomes. METHODS: The SEER database was queried for patients with supraglottic SCCa from 1973 to 2013. Information on demographics; tumor size; histologic grade; American Joint Committee on Cancer (AJCC) stage; SEER local, regional, distant stage; and treatment modality were analyzed. RESULTS: There were 22,675 cases of primary supraglottic SCCa identified. The mean age at diagnosis was 62.3 years, with males accounting for 70.3% of all cases. A high percentage of patients presented with stage IV disease (44.9%). The most common treatment modality was radiotherapy (46.6%), followed by combination of surgery and radiotherapy (29.2%) and surgery alone (15.0%). Overall 5-year disease-specific survival (DSS) for all cases was 54.0%. When stratified by treatment modality, 5-year DSS was best for patients receiving surgery alone (64.2%). However, for patients with AJCC stage IV disease, survival was significantly better with combined surgery and radiotherapy (52.5%). CONCLUSION: In general, supraglottic SCCa is treated most commonly with radiotherapy, followed by surgery and radiotherapy. Patients managed surgically had better 5-year DSS when compared to patients treated by other modalities. However, when stratified by stage, patients with AJCC stage IV disease had significantly better survival with combined surgery and radiotherapy. Of patients receiving surgery, supraglottic laryngectomy was found to have a significantly better 5-year DSS when compared to both total laryngectomy and laryngectomy, not otherwise specified. LEVEL OF EVIDENCE: NA Laryngoscope, 129:1822-1827, 2019.
引用
- Patel TD, Echanique KA, Yip C, et al. Supraglottic Squamous Cell Carcinoma: A Population-Based Study of 22,675 Cases. Laryngoscope. 2018. PMID: 30536822. doi:10.1002/lary.27592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。